Background: The aim of this study was to evaluate postoperative complications in patients having major elective surgery using oesophageal Doppler monitor-guided goal-directed haemodynamic therapy (GDHT), in which administration of fluids, inotropes, and vasopressors was guided by stroke volume, mean arterial pressure, and cardiac index. Methods: The FEDORA trial was a prospective, multicentre, randomised, parallel-group, controlled patient-and observerblind trial conducted in adults scheduled for major elective surgery. Randomization and allocation were carried out by a central computer system. In the control group, intraoperative fluids were given based on traditional principles. In the GDHT group, the intraoperative goals were to maintain a maximal stroke volume, with mean arterial pressure >70 mm Hg, and cardiac index !2.5 litres min À1 m
Whether goal-directed haemodynamic therapy improves postoperative outcome is unclear. The effect of oesophageal Doppler cardiac output monitor guided haemodynamic therapy was compared with standard care in a multicentre randomised trial. Haemodynamic optimization reduced complications and hospital length of stay in lowemoderate risk patients having major abdominal surgery, with no effect on mortality. Goal-directed haemodynamic therapy can be beneficial even in lowemoderate risk patients.
Approximately 240 million anaesthesia procedures are performed annually worldwide. 1 Of these, approximately 10% are in high-risk patients. Although there is no consensus on the definition of 'high-risk' patients, 2 this group probably accounts for >80% of perioperative deaths. 3 Moderate-risk surgery is much more common and constitutes about 40% of total surgical procedures. Nearly 30% of moderate-risk surgical patients experience minor postoperative complications, most often gastrointestinal, including delayed enteral feeding, paralytic ileus, nausea or vomiting, and wound complications. 4 Even minor complications prolong hospital stay 5 and increase healthcare costs, 6 and, more importantly, can reduce long-term survival. 7 The European Surgical Outcomes Study in patients having non-cardiac surgery concluded that in-hospital mortality rate was high (4%) and varies substantially among European countries. 8 There were also large differences in postsurgery mortality among hospitals within each country, suggesting that there is a potential to improve survival after surgery. 9, 10 Many postoperative complications are thought to be related to tissue hypoperfusion and an imbalance between oxygen delivery and consumption. 11 Perioperative fluid management strongly influences patient outcomes. 12e14 Despite national guidelines 15, 16 and international recommendations, 17e20 there remains wide variability in haemodynamic monitoring, 21 and type and volume of administered fluids. 22, 23 Goal-directed hemodynamic therapy (GDHT) is a method aiming at optimal dosing and timing of fluids, inotropes, and vasopressors through monitoring of cardiac output (CO) and other haemodynamic parameters. Studies suggest that GDHT helps prevent organ hypoperfusion and fluid overload, thereby reducing postoperative complications. 24 However, the OPTI-MISE trial 12 and other recent studies 25e27 suggest that the benefits associated with GDHT are less than previously reported, and that GDHT can even worsen patient outcomes if combined with a liberal fluid maintenance regimen. 28 In particular, the usefulness of oesophageal Doppler monitoring (ODM) to guide GDHT has recently been questioned. 29, 30 We carried out a controlled randomized clinical trial to study the effect of ODM-guided administration of i.v. fluids and vasopressor and inotropic drugs on postoperative complications after major surgery. Specifically, we tested the hypothesis that ODMguided management reduces postoperative complications. 22) , and registered by the principal investigator (J.M.C.V.) in the clinical trial registry ISRCTN (ISRCTN93543537). The Ethics Committee at each centre approved the study protocol; the trial was conducted according to the original protocol, which remained unchanged throughout the duration of the trial. The full study protocol (in Spanish) is available upon request, and the summarized English version can be accessed at http://www. eargroup.es/. Written informed consent was obtained from all patients before surgery. The principal investigators (J.M.C.V. and S.A.L.) performed site visits for source data verification.
Methods

Study population
Eligible patients were aged 18 yr or older and scheduled for major abdominal, urological, gynaecological, or orthopaedic surgery under general anaesthesia using laparoscopic or open approaches. Surgery was considered major if it fulfilled at least one of the following criteria: expected duration !2 h, estimated blood loss >15% of blood volume, or transfusion requirements of at least two packs of red blood cells. Exclusion criteria were emergency surgery, ASA physical status 31 >3, contraindications for ODM, or aortic pathology that could lead to misinterpretation of haemodynamic variables (e.g. intraaortic balloon pump, thoracic aorta aneurysm). The principal investigator at each site evaluated eligibility, obtained informed consent, and enrolled participants.
was performed through a secure web-based system provided by 'Agencia Laín Entralgo' (Madrid, Spain). Eligible participants were randomised in a 1:1 ratio to the intervention or control groups. Allocation details were concealed in sequentially numbered, opaque, sealed and stapled envelopes. Envelopes were opened by the investigator on the day of surgery when patients were randomised. Subjects and physicians who collected data and evaluated patients during the postoperative period were blinded to the treatment allocation. However, it was impossible to blind the researchers who performed haemodynamic monitoring. All subjects received balanced anaesthesia, i.v. anaesthetic induction, and neuromuscular relaxants; for pragmatic reasons, their administration was at the discretion of the anaesthetist. Bispectral index monitoring (BIS; Medtronic, Dublin, Ireland) was used to monitor the depth of anaesthesia. Sevoflurane was used for anaesthesia maintenance, with a BIS target range of 40e60. Epidural anaesthesia, central venous catheter placement and invasive radial arterial blood pressure monitoring were performed per preference of the anaesthetist. All subjects had basic anaesthetic monitoring with fivelead ECG, pulse oximetry, and oscillometric blood pressure; at least one peripheral i.v. line was established. All subjects received standard measures to maintain oxygen saturation by pulse oximetry !94%, normothermia, and heart rate <100 beats min
À1
. Ventilation with inspired oxygen fraction of 60% was mechanically controlled to maintain PaCO 2 between 4.7 and 6.0 kPa, with a positive end-expiratory pressure of 4e6 mm Hg and tidal volume of 6e8 ml kg À1 .
In both groups, blood loss was compensated for by infusion of colloid in a 1:1 ratio. Packed red cells were transfused for haemoglobin <10 g dl À1 in subjects with cardiac comorbidities, or <7 g dl À1 in those without cardiac comorbidities. 
Control group
GDHT group
Subjects in the intervention group were given i.v. fluids, vasopressors, and inotropes according to a haemodynamic algorithm shown in Fig. 1 . Intraoperative haemodynamic monitoring was conducted using ODM of CO (CardioQ, EDM; Deltex Medical, Inc., Chichester, UK). The manufacturer of the ODM system provided training to all investigators before the start of the clinical trial. The haemodynamic protocol was initiated after insertion of the probe and continued until the end of surgery. At the beginning of surgery, subjects received an initial haemodynamic assessment based on stroke volume (SV), cardiac index (CI), and mean arterial pressure (MAP). First, preload was optimized by crystalloid loading to achieve and maintain a maximal SV. In addition to routine fluid management, subjects were given 250 ml boluses of crystalloid solution. If SV increased by 10% or more, the fluid challenge was repeated. If, after two crystalloid boluses, the subjects required more fluids to optimize SV, colloid (HES) boluses were given. Fluid challenges of 250 ml were repeated until the SV failed to increase by 10%. At this point, preload was considered optimized, and SV was determined and used as the haemodynamic goal until the end of surgery. No further colloid fluid boluses were given until a 10% decrease in SV occurred. In patients with no response to fluid challenge, inotropes were given to reach a minimum CI (2.5 litres min À1 m À2 ), which served as a safety parameter to prevent low CO. If SV was optimized and CI was within the target range but MAP was <65 mm Hg, vasopressors were given. Every 5 min, subjects were reassessed to maintain values within the desired range, and haemodynamic data were recorded. At the end of surgery total catecholamine administration, estimated blood loss, urine output, and infused fluid volumes were recorded.
End points
The primary endpoint was the percentage of patients who developed pre-defined moderate or severe postoperative complications within 180 days of surgery, including complications that occurred before or after discharge from hospital and required outpatient or inpatient care. Data were obtained from subject history and by telephone follow-up at 180 days after surgery. Initial definition of postoperative complications was based on the guidelines of the American College of Surgeons National Surgical Quality Improvement Program published in 2011. 33 However, after the standards for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine guidelines 34 were updated in 2014, the definition of postoperative complications in the study were updated to align with the new standards, 35 a change that was made before unblinding and data analysis. Secondary end points were: length of hospital stay (LOS; defined as the number of days spent in the hospital from the day of surgery to hospital discharge or death), length of stay in the intensive care unit, re-interventions, time to onset of oral tolerance and time to ambulation, and all-cause mortality at 180 days after surgery.
Sociodemographic and clinical data, ASA physical status, 31 comorbidities, and preoperative haemoglobin were recorded at baseline. Functional status was described via metabolic energy equivalents. 36 Data were recorded in case report forms at each site by blinded investigators; postoperative data were obtained from clinical records completed by surgeons and anaesthetists responsible for patient care (blinded to the allocation). Data were uploaded in the database created for the study; this database could be accessed only by the trial principal investigator and the statistician (J.M.C.V., C.F.P.) who analysed the data. Data validation was conducted by the principal investigator (J.M.C.V.) and an external advisor (A.A.G.). The study was performed and is reported in accordance with CONSORT guidelines. 35 
Statistical analysis
Sample size calculation was based on a meta-analysis of randomised clinical trials of ODM in colorectal resection, which reported a 30% incidence of complications in the ODM group, compared with 49% in the control group. 37 A total of 105 subjects per arm would be needed to detect a 19% difference in the incidence of complications between GDHT and control with a power of 80% and a error of 0.05. We thus planned to recruit an equal number of subjects for each type of surgery (abdominal, urological, gynaecological, or orthopaedic), resulting in a total of 840 patients. As a result of low recruitment, we decided posthoc to exclude the orthopaedic subgroup for analysis. The analysis was carried out on a modified intention to treat basis (all randomized subjects who received the study treatment). Qualitative variables were described using frequency distribution, and quantitative variables were described by mean and standard deviation (SD) in case of normal distribution or median (inter-quartile range) in case of asymmetric distribution. Potential confounders were selected to adjust the primary effect of the study. The primary outcome was expressed as percentage of subjects with postoperative complications. Odds ratios and 95% confidence intervals, both univariate and adjusted to a logistic model with bootstrap estimate, were calculated. Quantitative secondary objectives were assessed 
Results
A total of 450 subjects were enrolled, and 428 were randomised between 2011 and 2014, with 224 allocated to the GDHT algorithm and 226 to standard care. Twenty-two subjects did not receive study treatment and were not included in the analysis (Fig. 2) . There were no patients lost to follow-up. The resolution of the Committee on Pharmacovigilance Risk Assessment of the European Medicines Agency/606.303 of October 2013 38 recommended not to use 6% HES in septic, burned, and critically ill patients, and in clinical trials and in situations of hypovolaemia. 39 The confusion generated by the restrictions in the use of HES led to a major decrease in recruitment, as HES was the only colloid permitted by the study protocol. Due to the low rate of patient recruitment, we were forced to stop the study in 2014. In addition, we decided to exclude orthopaedic patients from the outcome analysis after recruiting only eight patients in this subgroup. Thus, 209 patients were included in the GDHT group and 211 in the control group, including only abdominal surgical procedures. Baseline subject characteristics were similar between groups (Table 1) , although there were more subjects with diabetes mellitus, chronic obstructive pulmonary disease, or chronic alcohol consumption in the GDHT arm (Table 1) . There were more subjects with ASA physiological status 3 in the GDHT group. Mean surgery duration was similar between groups. Most subjects underwent major gastrointestinal surgery. Distribution of subjects between the surgery categories and approaches was similar in the two arms ( Table 2) .
One subject suffered nasal trauma with epistaxis caused by nasal insertion of the oesophageal probe.
The percentage of subjects who experienced moderate or severe complications was lower in the GDHT group than in control group [8.6% vs 16.6%, P¼0.018, odds ratio ¼0.48 (95% confidence interval: 0.27e0.89; relative risk reduction ¼48%). A significant reduction of complications was observed only in patients undergoing gastrointestinal surgery (Fig. 3) . There were fewer subjects who suffered moderate or severe acute kidney injury (AKI), acute respiratory distress syndrome, acute pulmonary oedema, pneumonia, or superficial or deep surgical site infection in the GDHT group. No significant differences in other complications were observed. Notably, we found no significant difference in the incidence of moderate or severe anastomotic breakdown between the groups: one subject (0.48%) in the GDHT group vs five subjects (2.4%) in the control group.
Analysis of secondary outcomes revealed a significant reduction in LOS (P¼0.002), length of intensive care unit stay (P<0.001), time to oral tolerance (P<0.001), and time to ambulation (P<0.001) in the GDHT group (Table 3 ). There was no significant difference in the percentage of subjects who were re-operated [13% (SD 6.2%) in the GDHT group vs 25% (11.8%) in the control group], or in all-cause mortality at 180 days of follow-up [10% (4.8%) in the GDHT group vs 9% (4.5%) in the control group] ( Table 2 ). Blood loss, transfusion requirements, and overall volume of intraoperative i.v. colloid and crystalloid fluids infused was similar (Tables 2 and 3 ). Volume of fluids administered postoperatively and use of vasoactive drugs (norepinephrine and dobutamine) was comparable (Tables 2  and 3 ). MAP and heart rate changes over time were similar between groups. A summary of the haemodynamic variables is shown in Table 4 .
Discussion
A haemodynamic optimization algorithm for management of low-moderate risk patients having major abdominal surgery significantly reduced postoperative complications in the 180 days after surgery. There was a decrease in AKI, acute respiratory distress syndrome, acute pulmonary oedema, pneumonia, and superficial or deep surgical site infection. LOS was shortened, although no difference in mortality at 180 days was found.
Haemodynamic monitoring and guided fluid administration should allow for early detection and prompt problem rectification thus of change to minimize organ damage related to inadequate oxygen supply. Adjustments in administration of fluids and drugs must be performed in a timely manner to avoid both insufficient organ perfusion and fluid overload. 40 Numerous trials and meta-analyses show that GDHT reduces postoperative complications and mortality in high-risk surgical patients, 12, 41, 42 regardless of the choice of monitoring method or target variables. 43e45 However, a recent metaanalysis and several trials 26, 30, 46 suggest that the benefits of GDHT might be less pronounced than previously believed, especially in lowemoderate risk patients. Thus, the question of whether GDHT improves postoperative outcomes is unclear.
47e49
Several reasons could explain the observed discrepancies between different trials including differences in trial design, patient populations, haemodynamic protocols in the intervention groups and standard of care in the control groups. In many cases, low sample size and insufficient statistical power existed to demonstrate significant differences. 12, 25 In our study, there were significantly fewer subjects with AKI in the intervention group, despite similar net amounts of perioperative fluids, both crystalloid and colloid, and no differences in the number of subjects treated intraoperatively with vasopressors or inotropes. Several studies show that GDHT decreases the incidence of postoperative AKI, 50 including when, as in our study, the amounts of perioperative fluids administered to intervention and control arms were similar. 51 This suggests that the benefits of GDHT can be attributed not only to providing additional fluids where required, but also to guided and responsive fluid usage and to avoiding unnecessary fluid delivery when haemodynamic objectives are met.
52
While there is general agreement that GDHT is beneficial in high-risk surgical patients, 41 ,53 use of GDHT in surgical patients with low-moderate risk is still controversial. 14,54 Stroke volume optimization could lead to fluid overload, 28 especially with liberal maintenance fluid. 46 A systematic review 55 and recent randomised controlled trials show that liberal administration of fluid and salt can be deleterious compared with a more restrictive regimen. 56, 57 Many centres now recommend baseline intraoperative crystalloid infusion of 1.5 ml kg À1 h À1 . 17 Against this background, our trial could be criticized for an excessively liberal standard fluid regimen. Indeed, we used a fluid maintenance currently considered liberal 28 ; however, it was more restrictive than what was considered liberal when the study was initiated (perioperative infusion >5 litres day À1 ). 28, 46 In our study, and similarly to other studies, 40, 44 we found no differences in the amounts of intraoperative or postoperative fluids, nor in use of vasopressors or inotropes. Likewise, we did not find differences in the MAP or heart rate. Therefore, the beneficial effect of GDHT could be due to administration of fluids at the right time, avoiding situations of hypovolaemia and hypoperfusion. Unlike other studies, 44 we did not use
supranormal CI values as a goal, but rather relied on SV optimization, which is less dependent on other factors such as hypnosis or analgesia that influence heart rate and therefore CI. Although we did not measure oxygen demand, our algorithm was designed to optimize intravascular volume in order to improve tissue perfusion and oxygenation, optimizing SV with fluids, limiting use of inotropes to subjects with CI <2.5 l min À1 m À2 . Another possible explanation is that in securing splanchnic circulation by GDHT, systemic inflammatory response to surgical trauma was reduced, similar to a study in which 108 subjects undergoing colorectal resection were randomised to intraoperative GDHT compared with standard fluid therapy (3640 ml vs 3830 ml) which showed that GDHT reduced concentrations of interleukin 6. 40 This leads to the hypothesis that the effect is due to timing; not only is tissue ischaemia avoided but fluid loading at inappropriate times is avoided. Excess fluid given at the wrong time can result in fluid overload and damage the endothelial glycocalyx, promoting further oedema and postoperative complications.
18
Infectious complications were significantly lower in the GDHT group, consistent with a recent meta-analysis demonstrating that GDHT reduced surgical site infections and pneumonia. 58 Despite fewer subjects with complications, mortality was similar at 180 days. Nonetheless, it is possible that a longer-term follow-up would reveal an effect on postsurgery deaths. 53 The major strength of this study is, unlike recent studies, 59, 60 we that have found a significant reduction in moderate-severe postoperative complications in patients who were not at high surgical risk. Identification of the specific patient populations most likely to benefit from GDHT is thus important in future studies. 61 In addition, our pragmatic approach increases external validity by approximating routine clinical practice. Our study has also limitations. First, the person performing intraoperative haemodynamic monitoring was not blinded. To compensate for this, blinded researchers performed data collection and followed subjects after surgery. In addition, haemodynamic values were not collected in the control group, so we cannot state that CI or SV values were better in the GDHT group. Second, postoperative fluid management in the intensive care unit was not standardized. Although overall postoperative fluid volumes infused were similar, we do not have details about exact timing of fluid administration and cannot exclude the possibility that poor postoperative fluid management skewed the effects of intraoperative fluid optimization. For all the above, we cannot exclude that the control group received worse perioperative management than the intervention group due to performance bias; it is possible that other perioperative factors in addition to GDHT affected the results. Third, although the outcomes were predefined, it is possible that some subjectively measured postoperative complications might have been underestimated due to intrinsically less accurate analysis. Fourth, discharge criteria were not predefined, which can limit the interpretation of LOS parameters. Undoubtedly, LOS is an important factor for the patient and for the healthcare system. However, it is obvious that it is affected by many aspects besides postoperative complications, including preoperative fitness and health, as well as social, structural, and logistical aspects of patients and each health care system. Finally, although recruiting large groups of patients undergoing different types of surgery was initially planned, the actual patient population was largely composed of abdominal surgery patients, as this was the only group for which the estimated sample size was reached. Moreover, this study might have insufficient statistical power to determine whether GDHT reduced postoperative complications as its incidence was lower than expected, both in the control group and in the GDHT group, probably because we estimated sample size based on studies before 2006. 37 During the last decade, enhanced recovery after surgery (ERAS) protocols 62, 63 have been integrated in most centres, although during the execution of this clinical trial there were no ERAS clinical pathways in any of the included centres. ERAS components have been integrated as a standard clinical practice in Europe, which together with improvement in surgical techniques has reduced postoperative complications considerably.
In conclusion, use of an oesophageal Doppler-guided haemodynamic algorithm reduced the incidence of moderate or severe postoperative complications and length of hospital stay in lowemoderate risk patients having major intermediate-risk surgery. However, mortality at 180 days was not affected.
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